[go: up one dir, main page]

ATE202115T1 - Pth und pthrp analoge deren herstellung und verwendung für die behandlung von osteoporosis. - Google Patents

Pth und pthrp analoge deren herstellung und verwendung für die behandlung von osteoporosis.

Info

Publication number
ATE202115T1
ATE202115T1 AT93917060T AT93917060T ATE202115T1 AT E202115 T1 ATE202115 T1 AT E202115T1 AT 93917060 T AT93917060 T AT 93917060T AT 93917060 T AT93917060 T AT 93917060T AT E202115 T1 ATE202115 T1 AT E202115T1
Authority
AT
Austria
Prior art keywords
laa
haa
pth
treatment
production
Prior art date
Application number
AT93917060T
Other languages
English (en)
Inventor
John L Krstenansky
John J Nestor Jr
Teresa L Ho
Brian H Vickery
Chinh T Bach
Original Assignee
Syntex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex Inc filed Critical Syntex Inc
Application granted granted Critical
Publication of ATE202115T1 publication Critical patent/ATE202115T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT93917060T 1992-07-14 1993-07-13 Pth und pthrp analoge deren herstellung und verwendung für die behandlung von osteoporosis. ATE202115T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/915,247 US5589452A (en) 1992-07-14 1992-07-14 Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis
PCT/US1993/006465 WO1994001460A1 (en) 1992-07-14 1993-07-13 Analogs of pth and pthrp, their synthesis and use for the treatment of osteoporosis

Publications (1)

Publication Number Publication Date
ATE202115T1 true ATE202115T1 (de) 2001-06-15

Family

ID=25435450

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93917060T ATE202115T1 (de) 1992-07-14 1993-07-13 Pth und pthrp analoge deren herstellung und verwendung für die behandlung von osteoporosis.

Country Status (17)

Country Link
US (8) US5589452A (de)
EP (2) EP0651765B1 (de)
JP (1) JP4106082B2 (de)
KR (3) KR100404008B1 (de)
AT (1) ATE202115T1 (de)
AU (1) AU671851B2 (de)
CA (1) CA2140281C (de)
DE (1) DE69330347T2 (de)
DK (1) DK0651765T3 (de)
ES (1) ES2159293T3 (de)
FI (1) FI120586B (de)
GR (1) GR3036521T3 (de)
HU (2) HU217843B (de)
MX (1) MX9304226A (de)
NZ (1) NZ254554A (de)
PT (1) PT651765E (de)
WO (1) WO1994001460A1 (de)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5814603A (en) * 1992-06-12 1998-09-29 Affymax Technologies N.V. Compounds with PTH activity
US5977070A (en) * 1992-07-14 1999-11-02 Piazza; Christin Teresa Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis
US5821225A (en) * 1992-07-14 1998-10-13 Syntex (U.S.A.) Inc. Method for the treatment of corticosteroid induced osteopenia comprising administration of modified PTH or PTHrp
US5589452A (en) * 1992-07-14 1996-12-31 Syntex (U.S.A.) Inc. Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis
AU672790B2 (en) * 1992-07-15 1996-10-17 Novartis Ag Variants of parathyroid hormone and its fragments
CN1070500C (zh) * 1993-07-13 2001-09-05 森德克斯(美国)股份有限公司 甲状旁腺激素类似物和甲状旁腺激素相关肽：合成和治疗骨质疏松症的用途
US5955425A (en) * 1996-08-02 1999-09-21 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
US6110892A (en) * 1994-06-20 2000-08-29 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
US6544949B1 (en) * 1995-07-13 2003-04-08 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Analogs of parathyroid hormone
US7410948B2 (en) * 1995-07-13 2008-08-12 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Analogs of parathyroid hormone
US5723577A (en) * 1995-07-13 1998-03-03 Biomeasure Inc. Analogs of parathyroid hormone
US5969095A (en) * 1995-07-13 1999-10-19 Biomeasure, Inc. Analogs of parathyroid hormone
US5955574A (en) * 1995-07-13 1999-09-21 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A. Analogs of parathyroid hormone
AU1558197A (en) * 1996-02-01 1997-08-22 Chugai Seiyaku Kabushiki Kaisha Preventives and remedies for thrombocytopenia
TW505654B (en) * 1996-07-30 2002-10-11 Hoffmann La Roche Synthesis of analogs of PTH and PTHrP
WO1998004591A1 (en) * 1996-07-31 1998-02-05 The General Hospital Corporation Novel parathyroid hormone-related peptide analogs
CN1176947C (zh) * 1996-08-02 2004-11-24 加拿大国家研究委员会 用于治疗骨质疏松症的甲状旁腺激素类似物
US6273634B1 (en) 1996-11-22 2001-08-14 Shell Oil Company Connector for an expandable tubing string
US6335195B1 (en) * 1997-01-28 2002-01-01 Maret Corporation Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation
US20020168718A1 (en) * 1997-04-03 2002-11-14 California Institute Of Technology Enzyme-mediated modification of fibrin for tissue engineering
JP2001523233A (ja) * 1997-04-17 2001-11-20 グラクソ、グループ、リミテッド 混合物の統計的デコンボルーション
HUP0003349A3 (en) * 1997-05-14 2001-12-28 Aventis Pharmaceuticals Inc Co Peptide parathyroid hormone analogs, pharmaceutical compositions comprising thereof and their use
JP2002509854A (ja) * 1997-09-09 2002-04-02 エフ．ホフマン−ラ ロシュ アーゲー ＰＴＨｒＰ類似体を使用する骨折治癒
US6248587B1 (en) 1997-11-26 2001-06-19 University Of Southern Cailfornia Method for promoting mesenchymal stem and lineage-specific cell proliferation
US6239109B1 (en) 1998-02-09 2001-05-29 University Of Southern California Method of promoting erythropoiesis
US7173011B2 (en) * 2000-11-20 2007-02-06 University Of Southern California Radiation therapy methods
US6455500B1 (en) 1998-03-10 2002-09-24 University Of Southern California Radiation therapy methods
US6498138B1 (en) 1998-03-11 2002-12-24 University Of Southern California Method of promoting production of living tissue equivalents
CA2327509A1 (en) 1998-05-05 1999-11-11 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R Pth2 receptor selective compounds
JP2003521441A (ja) 1998-05-11 2003-07-15 ユニヴァースティ オブ サザーン カリフォルニア 化学療法後の白血球生残率を増加させる方法
US6762167B1 (en) 1998-05-11 2004-07-13 University Of Southern California Methods for treating a patient undergoing chemotherapy
JP3686335B2 (ja) 1998-07-13 2005-08-24 ユニヴァースティ オブ サザーン カリフォルニア 骨および軟骨成長と修復を促進する方法
US6916783B2 (en) 1998-07-13 2005-07-12 University Of Southern California Methods for accelerating bone and cartilage growth and repair
WO2000009144A1 (en) 1998-08-13 2000-02-24 University Of Southern California Methods to increase blood flow to ischemic tissue
US7601685B2 (en) * 1998-08-27 2009-10-13 Eidgenossische Technische Hochschule Zurich Growth factor modified protein matrices for tissue engineering
US6894022B1 (en) * 1998-08-27 2005-05-17 Eidgenossische Technische Hochschule Zurich Growth factor modified protein matrices for tissue engineering
US7241730B2 (en) 1998-08-27 2007-07-10 Universitat Zurich Enzyme-mediated modification of fibrin for tissue engineering: fibrin formulations with peptides
US6495662B1 (en) 1998-10-22 2002-12-17 The General Hospital Corporation Bioactive peptides and peptide derivatives of parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHrP)
WO2000031137A1 (en) * 1998-11-25 2000-06-02 The General Hospital Corporation Amino-terminal modified parathyroid hormone (pth) analogs
AU4217299A (en) * 1998-11-30 2000-06-19 General Hospital Corporation, The Pth1r and pth3r receptors, methods and uses thereof
US7820393B2 (en) * 1999-01-14 2010-10-26 Scantibodies Laboratory, Inc. Methods, kits and antibodies for detecting parathyroid hormone
US6689566B1 (en) 1999-01-14 2004-02-10 Scantibodies Laboratory, Inc. Methods, kits, and antibodies for detecting parathyroid hormone
US6730775B1 (en) 1999-03-23 2004-05-04 University Of Southern California Methods for limiting scar and adhesion formation
US7338938B2 (en) * 1999-05-10 2008-03-04 University Of Southern California Methods for treating a patient undergoing chemotherapy
WO2004028444A2 (en) * 1999-06-02 2004-04-08 Scantibodies Laboratory, Inc. Parathyroid hormone antagonists and uses thereof
US6923968B2 (en) * 2000-08-10 2005-08-02 Scantibodies Laboratory, Inc. Cyclase inhibiting parathyroid hormone antagonists or modulators and osteoporosis
US20080108086A1 (en) * 1999-06-02 2008-05-08 Cantor Thomas L Parathyroid hormone antagonists and uses thereof
US7022815B1 (en) 1999-09-29 2006-04-04 The General Hospital Corporation Polypeptide derivatives of parathyroid hormone (PTH)
AU7734800A (en) * 1999-09-29 2001-04-30 General Hospital Corporation, The Polypeptide derivatives of parathyroid hormone (pth)
EP1222208B1 (de) 1999-09-29 2008-10-29 The General Hospital Corporation Parathyroid hormon (pth) polypeptidderivate
GB9924351D0 (en) * 1999-10-14 1999-12-15 Brennan Frank Immunomodulation methods and compositions
CA2398583A1 (en) * 2000-02-11 2001-08-16 Cellomics, Inc. Peptide biosensors for anthrax protease
US20050124537A1 (en) * 2000-04-27 2005-06-09 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
US6756480B2 (en) * 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
US7226442B2 (en) * 2000-10-10 2007-06-05 Microchips, Inc. Microchip reservoir devices using wireless transmission of power and data
AU2002308522A1 (en) * 2001-05-01 2002-11-11 University Of Southern California Methods for inhibiting tumor cell proliferation
DE10123668A1 (de) * 2001-05-16 2002-11-28 Johein Harmeyer Anwendung einer Hormonpräparation zur Induzierung und Stimulierung des intestinalen Calciumtransports
US20030232324A1 (en) * 2001-05-31 2003-12-18 Chiron Corporation Chimeric alphavirus replicon particles
KR100491737B1 (ko) * 2001-07-20 2005-05-27 주식회사 한국아이템개발 공기 정화 기능의 모기 퇴치기
US7572765B2 (en) 2001-07-23 2009-08-11 The General Hospital Corporation Conformationally constrained parathyroid hormone (PTH) analogs
JPWO2003024486A1 (ja) * 2001-09-17 2004-12-24 中外製薬株式会社 骨量減少症治療剤
US7247609B2 (en) * 2001-12-18 2007-07-24 Universitat Zurich Growth factor modified protein matrices for tissue engineering
ATE386545T1 (de) * 2001-12-18 2008-03-15 Eth Zuerich Wachstumsfaktor-modifizierte proteinmatrizes zur geweberekonstruktion (tissue engineering)
EP1531855A4 (de) * 2002-01-10 2009-07-22 Osteotrophin Llc Behandlung von knochenerkrankungen mit skelettalen anabolika
JPWO2003064462A1 (ja) * 2002-02-01 2005-05-26 中外製薬株式会社 Ｐｅｇ結合ｐｔｈ又はｐｅｇ結合ｐｔｈ誘導体
EP1513547A4 (de) * 2002-05-23 2009-11-04 Michael F Holick Verwendung von parathormone-peptid-analoga zur behandlung von scheidenatrophie
AU2003278766A1 (en) * 2002-09-04 2004-03-29 Microchips, Inc. Method and device for the controlled delivery of parathyroid hormone
US20040067526A1 (en) * 2002-10-03 2004-04-08 Cantor Thomas L. Methods for diagnosing and guiding treatment of bone turnover disease
US8263666B2 (en) 2002-10-29 2012-09-11 L'oreal Composition in the form of an oil-in-water emulsion and uses thereof
EP1567178A4 (de) * 2002-11-01 2009-07-15 Amgen Inc Modulatoren von rezeptoren für nebenschilddrüsenhormon- und nebenschildsrüsenhormonbezogene proteine
US8088734B2 (en) * 2003-01-21 2012-01-03 Unigene Laboratories Inc. Oral delivery of peptides
EP1610813A4 (de) * 2003-03-19 2009-07-01 Gen Hospital Corp KONFORMATIONSEINGESCHRÄNKTE PARATHORMONE MIT a-HELIX-STABILISATOREN
KR100540659B1 (ko) * 2003-07-02 2006-01-10 삼성전자주식회사 이미지 확대 인쇄 방법과 장치 및 컴퓨터 프로그램을저장하는 컴퓨터로 읽을 수 있는 기록 매체
US7910544B2 (en) 2003-07-17 2011-03-22 The General Hospital Corporation Conformationally constrained parthyroid hormone (PTH) analogs
US7044468B2 (en) * 2003-10-15 2006-05-16 Sklansky Games, Llc System and method for playing community hand poker games utilizing dealer qualifying criteria
US7562876B2 (en) * 2003-10-15 2009-07-21 Sklansky Games, Llc System and method for playing community hand poker games utilizing mathematical dealer qualifying criteria
WO2005046798A1 (en) * 2003-11-12 2005-05-26 Nps Allelix Corp. Treatment of bone loss utilizing full length parathyroid hormone
WO2005072277A2 (en) * 2004-01-21 2005-08-11 Unigene Laboratories Inc. Amidated parathyroid hormone fragments and uses thereof
US7541140B2 (en) * 2004-06-03 2009-06-02 Scantibodies Laboratory, Inc. Assessing risk for kidney stones using parathyroid hormone agonist and antagonist
US7595294B2 (en) * 2004-10-08 2009-09-29 Transition Therapeutics, Inc. Vasoactive intestinal polypeptide pharmaceuticals
US20080214440A1 (en) * 2004-10-08 2008-09-04 Forbes Medi-Tech (Research), Inc. Vasoactive intestinal polypeptide compositions
MX2007004116A (es) * 2004-10-08 2007-10-05 Forbes Medi Tech Res Inc Composiciones farmaceuticas de polipeptidos intestinales vasoactivos.
US20070293429A1 (en) * 2004-10-08 2007-12-20 Therapei Pharmaceuticals, Inc. Vasoactive Intestinal Polypeptide Compositions
US20090170775A1 (en) * 2004-10-08 2009-07-02 Transition Therapeutics, Inc. Vasoactive intestinal polypeptide compositions
AU2005318097A1 (en) * 2004-12-22 2006-06-29 Kuros Biosurgery Ag Michael-type addition reaction functionalised peg hydrogels with factor XIIIA incorporated biofactors
US8575101B2 (en) 2005-01-06 2013-11-05 Kuros Biosurgery Ag Supplemented matrices for the repair of bone fractures
WO2006073711A2 (en) * 2005-01-06 2006-07-13 Kuros Biosurgery Ag Use of a matrix comprising a contrast agent in soft tissues
EP1833522B1 (de) * 2005-01-06 2016-06-22 Kuros Biosurgery AG Ergänzte matrizen zur wiederherstellung von knochenbrüchen
AU2006208131A1 (en) * 2005-01-25 2006-08-03 Microchips, Inc. Control of drug release by transient modification of local microenvironments
WO2007059470A2 (en) * 2005-11-10 2007-05-24 Board Of Control Of Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
AR056806A1 (es) 2005-11-14 2007-10-24 Amgen Inc Moleculas quimericas de anticuerpo rankl- pth/ pthrp
DE102006014579A1 (de) * 2006-03-29 2007-10-04 Epcos Ag Verfahren zur Reinigung einer Monomer-Lösung und Herstellungsverfahren für ein elektrisches Bauelement umfassend das Reinigungsverfahren
WO2007133580A2 (en) * 2006-05-09 2007-11-22 Zelos Therapeutics, Inc. Use of pth (1-31) and optionally g-csf for hematopoietic stimulation
WO2008019062A2 (en) * 2006-08-04 2008-02-14 The General Hospital Corporation Polypeptide derivatives of parathyroid hormone (pth)
US8012694B2 (en) * 2006-09-14 2011-09-06 Immutopics, Inc. Assay for the detection of phosphorylated PTH
USRE49444E1 (en) 2006-10-03 2023-03-07 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
EP2073789B8 (de) * 2006-10-03 2022-09-14 Radius Health, Inc. Stabile zusammensetzung mit anabolischem knochenprotein, und zwar einem pthrp-analogon, sowie deren verwendung
US7803770B2 (en) * 2006-10-03 2010-09-28 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
CA2672907C (en) * 2006-10-13 2013-08-06 Eli Lilly And Company Pegylated pth as pth receptor modulators and uses thereof
JP2010523243A (ja) * 2007-04-13 2010-07-15 クロス・バイオサージェリー・アクチェンゲゼルシャフト 高分子組織シーラント
WO2009017809A2 (en) 2007-08-01 2009-02-05 The General Hospital Corporation Screening methods using g-protein coupled receptors and related compositions
CA2710798A1 (en) * 2007-12-28 2009-07-09 Kuros Biosurgery Ag Pdgf fusion proteins incorporated into fibrin foams
WO2009114461A2 (en) * 2008-03-10 2009-09-17 University Of Southern California Angiotensin (1-7) dosage forms and uses thereof
US8563513B2 (en) 2009-03-27 2013-10-22 Van Andel Research Institute Parathyroid hormone peptides and parathyroid hormone-related protein peptides and methods of use
AU2009356227A1 (en) 2009-12-07 2012-06-21 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
CA2799183A1 (en) 2010-05-12 2011-11-17 Radius Health, Inc. Therapeutic regimens
WO2011143406A2 (en) 2010-05-13 2011-11-17 The General Hospital Corporation Parathyroid hormone analogs and uses thereof
WO2012047617A1 (en) 2010-09-28 2012-04-12 Radius Health, Inc. Selective androgen receptor modulators
EP2686027B1 (de) 2011-03-16 2021-05-05 Kuros Biosurgery AG Pharmazeutische formulierung zur verwendung für die wirbelsäulenfusion
CA2836573C (en) * 2011-05-18 2022-06-07 Eumederis Pharmaceuticals, Inc. Improved peptide pharmaceuticals
US20200354428A9 (en) 2013-06-23 2020-11-12 Wisconsin Alumni Research Foundation Analogues of parathyroid hormone (1-34) that function as agonists of the parathyroid hormone receptor-1 and display modified activity profiles
EP3834824A1 (de) 2014-03-28 2021-06-16 Duke University Verfahren zur behandlung von krebs unter verwendung von selektiven östrogenrezeptormodulatoren
WO2016176664A1 (en) 2015-04-29 2016-11-03 Radius Health, Inc. Methods for treating cancer
CA3020333A1 (en) 2016-04-18 2017-10-26 Radius Health, Inc. Formulations of abaloparatide, transdermal patches thereof, and uses thereof
US20170368036A1 (en) 2016-06-22 2017-12-28 Radius Health, Inc. Ar+ breast cancer treatment methods
FI3565542T3 (fi) 2017-01-05 2024-06-24 Radius Pharmaceuticals Inc Rad1901-2hcl:n polymorfisia muotoja
US10996208B2 (en) 2017-04-28 2021-05-04 Radius Health, Inc. Abaloparatide formulations and methods of testing, storing, modifying, and using same
EP3755332A1 (de) 2018-02-21 2020-12-30 AI Therapeutics, Inc. Kombinationstherapie mit apilimod und glutamatergen mitteln
JP7473486B2 (ja) 2018-07-04 2024-04-23 ラジウス ファーマシューティカルズ，インコーポレイテッド Ｒａｄ１９０１－２ｈｃｌの多形形態
CN109734794A (zh) * 2019-03-07 2019-05-10 苏州科技大学 一种阿巴帕肽的制备方法
CN114057863B (zh) * 2020-08-06 2023-10-20 珠海联邦制药股份有限公司 一种甲状旁腺激素相关肽类似物及其应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) * 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
US4423037A (en) * 1982-05-13 1983-12-27 The General Hospital Corporation Inhibitors of peptide hormone action
US4643988A (en) * 1984-05-15 1987-02-17 Research Corporation Amphipathic peptides
US4738921A (en) * 1984-09-27 1988-04-19 Eli Lilly And Company Derivative of the tryptophan operon for expression of fused gene products
AU6104586A (en) * 1985-08-12 1987-02-19 Malcolm A. Martin Aids protein using trple gene
WO1988000596A1 (en) * 1986-07-18 1988-01-28 The University Of Melbourne A PROTEIN ACTIVE IN HUMORAL HYPERCALCEMIA OF MALIGNANCY-PTHrP
DE3683910D1 (de) * 1986-09-05 1992-03-26 Cetus Corp Oxidationsresistente muteine von beta-interferon, deren herstellung und diese muteine enthaltende praeparate.
US5010010A (en) * 1986-10-22 1991-04-23 Selmer-Sande, A.S. Production of human parathyroid hormone from microorganisms
US4833125A (en) * 1986-12-05 1989-05-23 The General Hospital Corporation Method of increasing bone mass
US4835255A (en) * 1987-03-26 1989-05-30 Yale University T-cell membrane protein
EP0293160A3 (de) * 1987-05-26 1990-05-09 Merck & Co. Inc. Parathyroid-Hormon-Antagonisten mit vergrösserten metabolischen Eigenschaften
US5001223A (en) * 1987-05-26 1991-03-19 Merck & Co., Inc. Parathyroid hormone antagonists with enhanced metabolic properties
US4771124A (en) * 1987-05-26 1988-09-13 Merck & Co., Inc. Parathyroid hormone antagonists with simplified synthetic methodology
EP0293158A3 (de) * 1987-05-26 1990-05-09 Merck & Co. Inc. Parathyroide Hormon-Antagonisten
DE3725319A1 (de) * 1987-07-30 1989-02-09 Biotechnolog Forschung Gmbh Pth-modifikationen und therapeutische zusammensetzungen, die sie enthalten und daraus bestehen
DE3725320A1 (de) * 1987-07-30 1989-02-09 Biotechnolog Forschung Gmbh Expressionsvektoren und verfahren unter deren verwendung zur gewinnung von cro/ss-galaktosidase/pth-fusionsproteinen und von pth
US4861756A (en) * 1988-03-08 1989-08-29 Merrell Dow Pharmaceuticals Inc. Synthetic pulmonary surfactant
US4968669A (en) * 1988-05-09 1990-11-06 Merck & Co., Inc. Parathyroid hormone antagonists
EP0341963A3 (de) * 1988-05-09 1991-07-24 Merck & Co. Inc. Parathyroidhormonhemmer
EP0411096A1 (de) * 1989-02-23 1991-02-06 Gesellschaft für Biotechnologische Forschung mbH (GBF) Pth-varianten kodierende dna-sequenzen, pth-varianten, expressionsvektor, bakterieller wirt, verwendung und therapeutische zusammensetzung
EP0470974B1 (de) * 1989-04-10 2000-01-26 Helix BioMedix, Inc. Lytische peptide, verwendung als wachstumsfördernde mittel und für infektionen und krebs
CA2040264A1 (en) * 1990-04-12 1991-10-13 Tatsuhiko Kanmera Parathyroid hormone antagonists
US5087562A (en) * 1990-04-25 1992-02-11 Merck & Co., Inc. Humoral hypercalcemic factor antagonists with modification at position 13 . . .
US5093233A (en) * 1990-04-25 1992-03-03 Merck & Co., Inc. Antagonists with position 13 modification
CA2087190A1 (en) * 1990-07-13 1992-01-14 Fred E. Cohen Parathyroid hormone analogues modified at positions
US5149779A (en) * 1990-07-26 1992-09-22 Merck & Co., Inc. Humoral hypercalcemic factor antagonists
JPH0532696A (ja) * 1990-09-28 1993-02-09 Takeda Chem Ind Ltd 副甲状腺ホルモン誘導体
WO1992011286A1 (en) * 1990-12-21 1992-07-09 Allelix Biopharmaceuticals Inc. Oxidation resistant variants of parathyroid hormone
US5317010A (en) * 1991-10-10 1994-05-31 Peter K. T. Pang Parathyroid hormone analogues substituted at AA 25, 26, 27, and use in osteoporosis treatment
US5434246A (en) * 1992-03-19 1995-07-18 Takeda Chemical Industries, Ltd. Parathyroid hormone derivatives
US5382658A (en) * 1992-04-03 1995-01-17 Allelix Biopharmaceuticals Inc. Stability-enhanced variants of parathyroid hormone
US5589452A (en) * 1992-07-14 1996-12-31 Syntex (U.S.A.) Inc. Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis

Also Published As

Publication number Publication date
EP1094073A3 (de) 2002-09-25
EP0651765B1 (de) 2001-06-13
HUT69628A (en) 1995-09-28
JPH07509228A (ja) 1995-10-12
CA2140281C (en) 2002-06-25
US5695955A (en) 1997-12-09
KR20030097580A (ko) 2003-12-31
CA2140281A1 (en) 1994-01-20
US5840837A (en) 1998-11-24
EP1094073A2 (de) 2001-04-25
US6051686A (en) 2000-04-18
FI120586B (fi) 2009-12-15
JP4106082B2 (ja) 2008-06-25
HU9500110D0 (en) 1995-03-28
KR950702578A (ko) 1995-07-29
DK0651765T3 (da) 2001-09-24
FI950169L (fi) 1995-01-13
US5807823A (en) 1998-09-15
US5693616A (en) 1997-12-02
KR100458350B1 (ko) 2004-11-26
HU217843B (hu) 2000-04-28
HU211348A9 (en) 1995-11-28
NZ254554A (en) 1996-03-26
EP0651765A1 (de) 1995-05-10
AU671851B2 (en) 1996-09-12
MX9304226A (es) 1995-01-31
DE69330347D1 (de) 2001-07-19
AU4670593A (en) 1994-01-31
PT651765E (pt) 2001-11-30
KR100404008B1 (ko) 2003-11-01
DE69330347T2 (de) 2002-05-29
WO1994001460A1 (en) 1994-01-20
US5798225A (en) 1998-08-25
US5874086A (en) 1999-02-23
ES2159293T3 (es) 2001-10-01
GR3036521T3 (en) 2001-12-31
KR100461618B1 (ko) 2005-04-06
FI950169A0 (fi) 1995-01-13
US5589452A (en) 1996-12-31

Similar Documents

Publication Publication Date Title
ATE202115T1 (de) Pth und pthrp analoge deren herstellung und verwendung für die behandlung von osteoporosis.
BR9608554A (pt) Processo de tratamneto de osteopenia induzida por corticosteróide
ATE50266T1 (de) Biologisch wirksame peptide strukturell mit regionen von wachstumshormonen in verbindung stehend.
PT81837A (en) Process for preparing oligopeptides and intermediates therefor
CA2206008A1 (en) Method for the synthesis of analogs of parathyroid hormone and parathyroid hormone related peptide
MY103251A (en) Biologically active molecules
PT88229A (pt) Processo para a preparacao de polipeptidos biologicamente activos
MX9709559A (es) Metodo para el tratamiento de osteopenia inducida por corticoesteroide.

Legal Events

Date Code Title Description
EEIH Change in the person of patent owner
UEP Publication of translation of european patent specification